Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing
- PMID: 29799955
- PMCID: PMC6145750
- DOI: 10.1001/jamainternmed.2018.1999
Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing
Abstract
This database analysis examines the extent to which pharmaceutical industry marketing of opioid products to physicians during 2014 was associated with opioid prescribing during 2015.
Conflict of interest statement
Figures

Comment in
-
Reduced Opioid Marketing Could Limit Prescribing Information for Physicians.JAMA Intern Med. 2018 Oct 1;178(10):1427. doi: 10.1001/jamainternmed.2018.4369. JAMA Intern Med. 2018. PMID: 30285131 No abstract available.
-
Reduced Opioid Marketing Could Limit Prescribing Information for Physicians-Reply.JAMA Intern Med. 2018 Oct 1;178(10):1426-1427. doi: 10.1001/jamainternmed.2018.4366. JAMA Intern Med. 2018. PMID: 30285139 Free PMC article. No abstract available.
References
-
- Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (WONDER). Atlanta, GA: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2017.
-
- Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav. 2017;74:63-66. - PubMed
-
- Centers for Medicare & Medicaid Services 2014 Program Year Open Payments Dataset. https://www.cms.gov/openpayments/explore-the-data/dataset-downloads.html. Published 2018. Accessed February 12, 2018.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources